The Law Office of James C. Kelly Announces Investigation of Inhibitex, Inc.
NEW YORK, Jan. 8, 2012 /PRNewswire/ -- The Law Office of James C. Kelly announces that it is investigating potential claims against the board of directors of Inhibitex, Inc. ("Inhibitex" or the "Company") (NasdaqCM: INHX) concerning possible breaches of fiduciary duty and other violations of law related to the Company's entry into an agreement to be acquired by Bristol-Myers Squibb Company ("Bristol-Myers") in a transaction with an approximate value of $2.5 billion.
Under the proposed agreement, Bristol-Myers will commence a tender offer to acquire all of the outstanding shares of Inhibitex's common stock at a price of $26.00 per share in cash.
The investigation concerns whether Inhibitex's board of directors adequately shopped the Company to obtain the best price possible for the Company's shareholders before entering into the agreement with Bristol-Myers.
If you are a holder of Inhibitex common stock and want to discuss your legal rights, you may e-mail or call The Law Office of James C. Kelly who will, without obligation or cost to you, attempt to answer your questions. Please contact James C. Kelly, Esq., of The Law Office of James C. Kelly, 477 Madison Avenue, New York, New York 10022, by toll free telephone at (888) 643-7517 or by sending an e-mail including your contact information to: [email protected].
The Law Office of James C. Kelly is a New York City-based law firm with significant experience representing investors in merger-related shareholder class actions, shareholder derivative actions, and securities fraud class actions. For more information about the firm, please visit its website at http://www.jckellylaw.com.
Attorney advertising. Prior results do not guarantee a similar outcome.
SOURCE The Law Office of James C. Kelly
Share this article